EVALUATION OF CA-M26, CA-M29, CA-15-3 AND CEA AS CIRCULATING TUMOR-MARKERS IN BREAST-CANCER PATIENTS

被引:41
|
作者
DNISTRIAN, AM [1 ]
SCHWARTZ, MK [1 ]
GREENBERG, EJ [1 ]
SMITH, CA [1 ]
SCHWARTZ, DC [1 ]
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021
关键词
BREAST CANCER; TUMOR-ASSOCIATED ANTIGENS; MUCIN TYPE GLYCOPROTEIN; TUMOR MARKERS; MONOCLONAL ANTIBODIES; IMMUNOASSAY;
D O I
10.1159/000217692
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical utility of CA M26 and CA M29 was studied in 116 breast cancer patients and compared with results for CA 15-3 and carcinoembryonic antigen (CEA). The highest sensitivities for breast cancer detection were achieved with CA 15-3 (0.60) and CEA (0.56), but this was compromised by a relative lack of specificity (0.87 and 0.88 for CA 15-3 and CEA, respectively). Sensitivities attained with CA M26 (0.47) and CA M29 (0.53) were lower, but there was an excellent specificity (1.00) for each assay in this series of benign patients. Tumor marker elevations were appreciable with advanced disease such that 82 of 91 patients (90%) with active metastatic breast cancer exhibited at least one abnormal test value. Longitudinal studies demonstrated that CA M26, CA M29, CA 15-3 and CEA complement each other and combinations of these markers reflect disease status better than individual tests.
引用
收藏
页码:82 / 90
页数:9
相关论文
共 50 条
  • [1] CA-M26 AND CA-M29 AS CIRCULATING TUMOR-MARKERS IN BREAST-CANCER
    SCHWARTZ, MK
    GREENBERG, E
    SMITH, C
    SCHWARTZ, DC
    DNISTRIAN, AM
    CLINICAL CHEMISTRY, 1990, 36 (06) : 1052 - 1052
  • [2] CORRELATION BETWEEN CHANGES IN THE TUMOR-MARKERS CA-M26 AND CA-M29 AND STANDARD RESPONSE EVALUATION IN PATIENTS WITH METASTATIC BREAST-CANCER
    VANDERGAAST, A
    HULSHOF, C
    KOK, TC
    VANLOON, E
    SPLINTER, TAW
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (06) : 870 - 873
  • [3] CA-15-3 AND CEA AS TUMOR-MARKERS IN BREAST-CANCER
    SCHOMMER, M
    MOBUS, V
    KREIENBERG, R
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1987, 242 (1-4) : 358 - 359
  • [4] IS FOLLOW-UP OF BREAST-CANCER WITH TUMOR-MARKERS CEA AND CA-15-3 JUSTIFIED
    FRITSCHE, E
    BENZ, J
    HELVETICA CHIRURGICA ACTA, 1992, 59 (01) : 225 - 229
  • [5] CLINICAL-EVALUATION OF NEW SERUM TUMOR-MARKERS CA M26 AND CA M29 IN PATIENTS WITH PRIMARY BREAST-CANCER
    ESKELINEN, M
    TIKANOJA, S
    BROWN, J
    ANTICANCER RESEARCH, 1990, 10 (04) : 959 - 962
  • [6] DIAGNOSTIC-SIGNIFICANCE OF THE TUMOR-MARKERS CEA, CA-15-3 AND CA-125 IN MALIGNANT EFFUSIONS IN BREAST-CANCER
    KANDYLIS, K
    VASSILOMANOLAKIS, M
    BAZIOTIS, N
    PAPADIMITRIOU, A
    TSOUSSIS, S
    FERDERIGOU, A
    EFREMIDIS, AP
    ANNALS OF ONCOLOGY, 1990, 1 (06) : 435 - 438
  • [7] COMPARISON OF CEA AND CA-15-3 AS METASTATIC BREAST-CANCER MARKERS
    NAMER, M
    PONSANICET, D
    KREBS, BP
    BULLETIN DU CANCER, 1987, 74 (06) : 684 - 684
  • [8] CARCINOMA-ASSOCIATED MUCIN SERUM MARKERS CA-M26 AND CA-M29 - EFFICACY IN DETECTING AND MONITORING PATIENTS WITH CANCER OF THE BREAST, COLON, OVARY, ENDOMETRIUM AND CERVIX
    YEDEMA, KA
    KENEMANS, P
    WOBBES, T
    VANKAMP, GJ
    DEBRUIJN, HW
    THOMAS, CM
    MASSUGER, LF
    SCHIJF, CP
    BON, GG
    VERMORKEN, JB
    VOORHORST, F
    HILGERS, J
    INTERNATIONAL JOURNAL OF CANCER, 1991, 47 (02) : 170 - 179
  • [9] THE TUMOR-MARKERS CA-125, CA-19-9, CA-15-3 AND CEA IN OVARIAN-CANCER
    HOFFMANN, L
    MULLERHAGEN, S
    FRANZ, G
    KLAPDOR, R
    DIETEL, M
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1987, 242 (1-4) : 371 - 372
  • [10] EVALUATION OF MCA, CA 15.3, CA M26, CA M29 IN BREAST-CANCER
    BUMMA, C
    BRAMARDI, AM
    LAURIA, G
    ARESE, P
    MARCHETTI, G
    JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES, 1990, 34 (04): : 29 - 32